We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including head and neck, lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
|Recent News||more >|
Kura Oncology Reports First Quarter 2017 Operational and Financial Results
Kura Oncology to Report First Quarter 2017 Financial Results
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
|Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed.|